

David A Pattison

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2259527/publications.pdf>

Version: 2024-02-01

51
papers

2,036
citations

361413

20
h-index

254184

43
g-index

56
all docs

56
docs citations

56
times ranked

2062
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 763-776. | 6.4 | 36 |
| 2 | [18F]GE-180 PET/CT assessment of enterocytic translocator protein (TSPO) over-expression: a pilot study in gastrointestinal GVHD. <i>Bone Marrow Transplantation</i> , 2022, 57, 517-519. | 2.4 | 3 |
| 3 | The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 66.e1-66.e9. | 1.6 | 20 |
| 4 | The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective. <i>Journal of Nuclear Medicine</i> , 2022, 63, 819-822. | 5.0 | 9 |
| 5 | Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 276.e1-276.e9. | 1.6 | 8 |
| 6 | All Prostate-specific Membrane Antigen Peptides Are Equal, but Some Are More Equal than Others. <i>European Urology Oncology</i> , 2022, 5, 283-284. | 5.4 | 2 |
| 7 | Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: ¹⁷⁷ Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS) – Final results.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4122-4122. | 1.6 | 11 |
| 8 | TheraP: ¹⁷⁷ Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel – Overall survival after median follow-up of 3 years (ANZUP 1603).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5000-5000. | 1.6 | 44 |
| 9 | ^{99m} Tc-Sestamibi Thyroid Scintigraphy in Amiodarone-Induced Thyrotoxicosis. <i>Clinical Nuclear Medicine</i> , 2022, 47, e582-e584. | 1.3 | 2 |
| 10 | ⁶⁸ Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 477-482. | 6.4 | 54 |
| 11 | PET detectives: Molecular imaging for pheochromocytomas and paragangliomas in the genomics era. <i>Clinical Endocrinology</i> , 2021, 95, 13-28. | 2.4 | 9 |
| 12 | ¹²⁴ I-PET/CT – Guided Diagnosis and Personalized Treatment of Metastatic Papillary Thyroid Cancer to the Pancreas. <i>Clinical Nuclear Medicine</i> , 2021, 46, 337-339. | 1.3 | 7 |
| 13 | Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1278-1284. | 5.0 | 25 |
| 14 | [¹⁷⁷ Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. <i>Lancet, The</i> , 2021, 397, 797-804. | 13.7 | 552 |
| 15 | Identification of Isolated Hepatic Sarcoidosis With ¹⁸ F-FDG PET/CT and MRI. <i>Clinical Nuclear Medicine</i> , 2021, 46, e448-e450. | 1.3 | 2 |
| 16 | UpFrontPSMA: a randomized phase 2 study of sequential ¹⁷⁷ Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol). <i>BJU International</i> , 2021, 128, 331-342. | 2.5 | 33 |
| 17 | Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4495-4507. | 6.4 | 41 |
| 18 | Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review. <i>Advances in Urology</i> , 2021, 2021, 1-9. | 1.3 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. <i>European Urology</i> , 2021, 80, 682-689. | 1.9 | 181 |
| 20 | Utility of ⁶⁸ Ga- ⁶⁸ DOTA-Exendin-4 positron emission tomography-computed tomography imaging in distinguishing between insulinoma and nesidioblastosis in patients with confirmed endogenous hyperinsulinaemic hypoglycaemia. <i>Internal Medicine Journal</i> , 2021, 51, 1657-1664. | 0.8 | 9 |
| 21 | Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging. <i>EJNMMI Research</i> , 2021, 11, 128. | 2.5 | 6 |
| 22 | Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of ¹⁷⁷ Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 857-865. | 5.0 | 191 |
| 23 | The utility of pharmacological and radiological interventions to optimize diagnostic information from PET/CT. <i>Cancer Imaging</i> , 2020, 20, 68. | 2.8 | 11 |
| 24 | Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): A case report. <i>Journal of Critical Care</i> , 2020, 60, 319-322. | 2.2 | 3 |
| 25 | Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol. <i>Thyroid</i> , 2019, 29, 1634-1645. | 4.5 | 69 |
| 26 | Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CT. <i>EJNMMI Research</i> , 2019, 9, 15. | 2.5 | 7 |
| 27 | ⁶⁴ Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 777-785. | 5.0 | 98 |
| 28 | Diagnostic challenges in a patient with an occult insulinoma: ⁶⁸ Ga- ⁶⁸ DOTA-Exendin-4 PET/CT and ⁶⁸ Ga- ⁶⁸ DOTATATE PET/CT. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 719-722. | 0.5 | 14 |
| 29 | Tumor Cystic Necrosis Following Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors. <i>Clinical Nuclear Medicine</i> , 2018, 43, 186-187. | 1.3 | 1 |
| 30 | Localisation of occult extra-pancreatic insulinoma using glucagon-like peptide-1 receptor molecular imaging. <i>Internal Medicine Journal</i> , 2018, 48, 97-98. | 0.8 | 4 |
| 31 | Lymphangitic Carcinomatosis From Prostate Cancer Identified With Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography Imaging. <i>Urology</i> , 2018, 114, e1-e2. | 1.0 | 4 |
| 32 | ¹⁸ F-FDG- ¹⁸ F-Avid Thyroid Incidentalomas: The Importance of Contextual Interpretation. <i>Journal of Nuclear Medicine</i> , 2018, 59, 749-755. | 5.0 | 35 |
| 33 | Management of Distant Metastasis in Differentiated Thyroid Cancer. , 2018, , 121-140. | | 0 |
| 34 | Targeted Molecular Imaging of Translocator Protein (TSPO) Using ¹⁸ FGE180-PET for the Diagnosis of Gastrointestinal Graft Versus host Disease (GI-GVHD). <i>Blood</i> , 2018, 132, 3397-3397. | 1.4 | 0 |
| 35 | THYROPET Study: Is It Biology or Technology That Is the Issue?. <i>Journal of Nuclear Medicine</i> , 2017, 58, 354.1-354. | 5.0 | 3 |
| 36 | Molecular imaging in the investigation of hypoglycaemic syndromes and their management. <i>Endocrine-Related Cancer</i> , 2017, 24, R203-R221. | 3.1 | 36 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3278-3287. | 3.6 | 125 |
| 38 | High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 476-489. | 6.4 | 42 |
| 39 | 68Ga-DOTATATE and 18F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity. <i>Cancer Imaging</i> , 2016, 16, 22. | 2.8 | 135 |
| 40 | Intense focal pituitary FDG uptake due to intravascular large B-cell lymphoma in pyrexia of unknown origin. <i>American Journal of Hematology</i> , 2016, 91, 1167-1168. | 4.1 | 2 |
| 41 | A New Theranostic Paradigm for Advanced Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1493-1494. | 5.0 | 10 |
| 42 | Quantitative assessment of thyroid-to-background ratio improves the interobserver reliability of technetium-99m sestamibi thyroid scintigraphy for investigation of amiodarone-induced thyrotoxicosis. <i>Nuclear Medicine Communications</i> , 2015, 36, 356-362. | 1.1 | 27 |
| 43 | Role of Fluorodeoxyglucose PET/Computed Tomography in Targeted Radionuclide Therapy for Endocrine Malignancies. <i>PET Clinics</i> , 2015, 10, 461-476. | 3.0 | 21 |
| 44 | Enhanced White Adipose Tissue Metabolism in Iatrogenic Cushing's Syndrome With FDG PET/CT. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3041-3042. | 3.6 | 11 |
| 45 | Intracoronary 99m Tc-Sestamibi Single Photon Emission Computed Tomography/Computed Tomography for Preoperative Evaluation of At-Risk Myocardium. <i>Circulation</i> , 2013, 128, 567-570. | 1.6 | 0 |
| 46 | Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines. <i>Andrology</i> , 2013, 1, 583-589. | 3.5 | 49 |
| 47 | An Endocrine Cause of Acute Post-partum Hypertension. <i>Obstetric Medicine</i> , 2013, 6, 30-32. | 1.1 | 7 |
| 48 | Amiodarone-Induced Destructive Thyroiditis Associated with Coronary Artery Vasospasm and Recurrent Ventricular Fibrillation. <i>European Thyroid Journal</i> , 2012, 2, 65-7. | 2.4 | 9 |
| 49 | Exercise-associated hyponatraemia on the Kokoda Track. <i>Medical Journal of Australia</i> , 2011, 194, 247-248. | 1.7 | 2 |
| 50 | Intermittent severe, symptomatic hyponatraemia due to the nephrogenic syndrome of inappropriate antidiuresis. <i>Annals of Clinical Biochemistry</i> , 2008, 45, 520-523. | 1.6 | 22 |
| 51 | Strongyloidiasis in personnel of the Regional Assistance Mission to Solomon Islands (RAMSI). <i>Medical Journal of Australia</i> , 2008, 189, 203-206. | 1.7 | 22 |